Holen Sie sich die Stockscreener-App
43.58
0.57%
-0.25
Schlusskurs vom Vortag:
$43.83
Offen:
$43.52
24-Stunden-Volumen:
2.49M
Relative Volume:
0.92
Marktkapitalisierung:
$11.68B
Einnahmen:
$2.17B
Nettoeinkommen (Verlust:
$521.27M
KGV:
24.62
EPS:
1.77
Netto-Cashflow:
$633.79M
1W Leistung:
-5.75%
1M Leistung:
+0.32%
6M Leistung:
-1.63%
1J Leistung:
+28.40%
1-Tages-Spanne:
$43.00
$43.73
1-Wochen-Bereich:
$43.00
$46.29
52-Wochen-Spanne:
$31.90
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Firmenname
Exelixis Inc
Sektor
Branche
Telefon
(650) 837-7000
Adresse
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Vergleichen Sie EXEL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
43.58 | 11.75B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-11-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Eingeleitet | Goldman | Buy |
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2024-09-19 | Eingeleitet | UBS | Neutral |
| 2024-04-11 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Eingeleitet | BTIG Research | Buy |
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-22 | Bestätigt | Oppenheimer | Outperform |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-09 | Eingeleitet | Wells Fargo | Overweight |
| 2023-01-26 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-03 | Fortgesetzt | Jefferies | Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Sell |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-18 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Eingeleitet | Goldman | Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Underweight |
| 2018-05-11 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-16 | Bestätigt | SunTrust | Buy |
| 2017-09-22 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-12 | Bestätigt | Needham | Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2017-03-31 | Eingeleitet | Needham | Buy |
| 2017-03-16 | Eingeleitet | Oppenheimer | Perform |
| 2017-02-28 | Herabstufung | Stifel | Buy → Hold |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Bestätigt | Stifel | Buy |
Alle ansehen
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
Aug Sectors: Is Exelixis Inc EX9 stock cheap vs fundamentalsEarnings Trend Report & Free Fast Entry Momentum Trade Alerts - moha.gov.vn
Exelixis Announces Key Senior Leadership Hires in Medical Affairs, Sales, & Marketing to Support Commercialization of Cabozan... - ADVFN
See How Rare Bullish Inflows Lift Outliers Like Exelixis - Yahoo Finance
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
Trading the Move, Not the Narrative: (EXEL) Edition - Stock Traders Daily
EXELExelixis Announces Second Quarter 2013 Financial Results - ADVFN
Does Exelixis (NASDAQ:EXEL) Deserve A Spot On Your Watchlist? - Yahoo Finance
Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data in Patients with Hepatocellular Carcinoma - ADVFN
Exelixis Announces Initiation of Investigator-Sponsored Clinical Trial Combining Cabozantinib & Abiraterone in Men With Castr... - ADVFN
Exelixis Announces Positive Overall Survival Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafeni... - ADVFN
Exelixis Inc Stock Analysis and ForecastLarge Cap Stability Picks & Double Or Triple Capital - earlytimes.in
Exelixis Announces Presentation of Updated Phase 1b Results for the Combination of Cobimetinib & Atezolizumab in Metastatic C... - ADVFN
Exelixis Announces Results from a Phase 2 Investigator-Sponsored Trial of Cabozantinib in the First-Line Treatment of Metasta... - ADVFN
Exelixis Receives $150 Million Funding Commitment From Deerfield Management - ADVFN
Exelixis Expands the Cabozantinib Development Program Through NCI-CTEP Collaboration - ADVFN
Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refract... - ADVFN
Exelixis Earnings Notes - Trefis
History Review: Is Exelixis Inc stock trading at a premium valuationPortfolio Return Summary & Free Expert Approved Momentum Trade Ideas - moha.gov.vn
Exelixis (MIC:EXEL-RM) EV-to-FCF : 0.00 (As of Dec. 26, 2025) - GuruFocus
Exelixis (HAM:EX9) EV-to-OCF : 13.21 (As of Dec. 22, 2025) - GuruFocus
Why Exelixis, Inc. (EXEL) Skyrocketed On Wednesday - MSN
Published on: 2025-12-21 13:28:36 - Улправда
How Exelixis Inc. stock reacts to job market dataMarket Risk Report & Safe Swing Trade Setups - ulpravda.ru
Behavioral Patterns of EXEL and Institutional Flows - news.stocktradersdaily.com
Published on: 2025-12-20 10:46:18 - Улправда
Can Exelixis Inc. stock hit analyst price targetsJuly 2025 Levels & Growth Focused Stock Reports - Улправда
Exelixis and Merck Advance LITESPARK-033: A New Kidney Cancer Combo With High-Stakes Market Potential - TipRanks
Exelixis (FRA:EX9) EV-to-OCF : 12.63 (As of Dec. 19, 2025) - GuruFocus
Will Exelixis Inc. stock benefit from infrastructure spendingJuly 2025 Sector Moves & AI Based Trade Execution Alerts - DonanımHaber
Gap Down: Can Exelixis Inc. (EX9) stock stage a strong rebound this quarterPortfolio Value Report & Short-Term Swing Trade Alerts - DonanımHaber
Is Exelixis Inc. stock a defensive play in 2025July 2025 Levels & Real-Time Market Trend Scan - DonanımHaber
Rally Mode: How analysts revise price targets for Exelixis Inc. (EX9) stock2025 Biggest Moves & Precise Buy Zone Tips - Улправда
Stelios Papadopoulos brings the long view on biotech on The BioCentury Show - biocentury.com
Returns Recap: How Exelixis Inc EX9 stock compares with top peersQuarterly Profit Report & Real-Time Buy Zone Alerts - moha.gov.vn
Why Exelixis Inc. (EX9) stock stays on buy listsWeekly Profit Analysis & Verified Stock Trade Ideas - ulpravda.ru
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance
Citizens reiterates Market Outperform rating on Exelixis stock at $50 By Investing.com - Investing.com Canada
Exelixis, Inc.Common Stock (NQ: EXEL - FinancialContent
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term - Yahoo Finance
Analysts Are Bullish on Top Healthcare Stocks: Owlet (OWLT), Exelixis (EXEL) - The Globe and Mail
VP Haley Files To Sell 23,539 Of Exelixis Inc [EXEL] - TradingView — Track All Markets
Exelixis Inc (HAM:EX9)Valuation Measures & Financial Statistics - GuruFocus
Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE), Exelixis (EXEL) and Natera (NTRA) - theglobeandmail.com
Exelixis Inc (HAM:EX9) Dividend - GuruFocus
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era - The Manila Times
Exelixis (EXEL) Receives a Hold from RBC Capital - theglobeandmail.com
Exelixis stock holds steady as Stifel maintains $43 price target By Investing.com - Investing.com Canada
Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D DaySlideshow (NASDAQ:EXEL) 2025-12-11 - Seeking Alpha
EXEL to Host Research and Development Day in December - GuruFocus
Analyst Upgrade: Can Exelixis Inc EX9 stock stage a strong rebound this quarterSell Signal & Daily Profit Focused Stock Screening - moha.gov.vn
(EXEL) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Finanzdaten der Exelixis Inc-Aktie (EXEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):